FREE TRACKED SHIPPING ON ORDERS OVER $299 $150
Sale!

Retatrutide – 40mg

Original price was: $279.99.Current price is: $251.99.

10% OFFLaunch Celebration

Low stock — act fast!

SALE ENDS IN --D--H--M--S
SKU: RT-40MG Categories: ,
  • Research focus: Multi-receptor incretin and glucagon-signalling research
  • Compound class: GIP, GLP-1 and glucagon receptor agonist
  • Researchers are exploring: Appetite, blood-sugar and energy-balance signalling
Fast Order ProcessingIn-stock orders prepared promptly
Tracking ProvidedEmailed when your order is on its way
Canadian SupportHelp when you need it

RESEARCH AT A GLANCE

A clearer view of the research landscape

01

Primary pathway

Multi-receptor metabolic signalling

02

Researchers explore

energy balance, nutrient signalling and metabolic regulation

03

Research coverage

Emerging clinical and translational research

Retatrutide — 40mg

Product Overview

Retatrutide, also identified in research as LY3437943, is a synthetic single-peptide agonist designed to engage glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.

Research Background

The compound provides a model for studying how three related receptor systems can be activated by one engineered ligand. These receptors are coupled to overlapping but distinct signalling networks, making retatrutide useful in receptor-potency, pathway-bias and integrated metabolic-signalling research.

Current Areas of Investigation

Published research includes recombinant receptor assays, cell-based cyclic-AMP studies, animal models and regulated clinical trials. Investigators examine receptor balance, downstream endocrine signalling and how multi-receptor pharmacology differs from selective GLP-1 or dual GIP/GLP-1 agonism.

In Plain Language

Researchers are studying whether activating three related hormone receptors together can influence appetite, blood-sugar regulation, energy use and body-weight-related metabolic pathways differently than targeting only one receptor. GIP and GLP-1 signalling are connected with nutrient response and fullness, while glucagon-receptor signalling adds another pathway involved in glucose and energy metabolism.

In plain terms, retatrutide research explores whether coordinating all three signals may produce broader metabolic changes than a single- or dual-receptor compound. Published trials have reported changes in food intake, body weight and glucose measures, while laboratory work continues to examine which receptor contributes to each observation.

Product Specifications

  • Catalogue No.: RT
  • Vial Size: 40mg

Quality & Documentation

Lot-specific product documentation and Certificate of Analysis (COA) information may be available through AURAPEP where applicable.

Research Use Only

RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for laboratory, analytical and research purposes. Not intended for self-administration or to diagnose, treat, cure or prevent any disease.

AURAPEP RESEARCH LIBRARY

Related Research

Explore the scientific background, evidence and limitations associated with this research compound.

Explore the complete Research Library

PRODUCT FAQ

Three common research questions

Explore concise, product-specific answers without leaving this page.

PRODUCT FAQ

Retatrutide – 40mg

01

What is Retatrutide and which pathway do researchers study?

Retatrutide is studied in relation to multi-receptor metabolic signalling. Researchers use it to investigate energy balance, nutrient signalling and metabolic regulation.

02

What are researchers investigating?

The current research landscape includes Emerging clinical and translational research. Study designs may involve biochemical assays, cell systems, animal models or regulated human research depending on the compound, and results should be interpreted within the limits of each model.

03

How does it differ from related research compounds?

Retatrutide is studied as a triple-receptor compound involving GIP, GLP-1 and glucagon signalling. This distinguishes it from semaglutide’s primarily GLP-1 activity and tirzepatide’s dual GIP/GLP-1 profile.

Research information is provided for scientific context. Product supplied for research use only.